14-3-3η Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis.
Walter P Maksymowych, Gilles Boire, Dirkjan van Schaardenburg...
https://pubmed.ncbi.nlm.nih.gov/26178283Actively Recruiting
Age: 18Years - 90Years
All Genders
ID00512239
Early Prediction of Patient-related and Radiological Outcomes in Patients With Recent-onset Inflammatory Polyarthritis (EPA) Using Established and Novel Independent Predictors
Led by Gilles Boire · Updated on 2025-03-25
1000
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
Sponsors
G
Gilles Boire
Lead Sponsor
T
The Arthritis Society, Canada
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying patients with early polyarthritis, including rheumatoid arthritis (RA), which is a common inflammatory joint disease causing disability and high costs. The trial aims to evaluate specific antibodies and other markers to predict which patients will have persistent or severe disease, helping doctors make better treatment decisions. This study focuses on patients with symptoms lasting less than 12 months to understand disease progression over time. This is a long-term observational study that follows about 390 adults with recent-onset inflammatory polyarthritis. Patients are regularly assessed over five years with blood tests, genetic analyses, and clinical evaluations. The study does not interfere with usual treatment. Researchers measure the presence of rheumatoid arthritis-specific autoantibodies, genetic markers, and other biological indicators to predict disease severity and treatment needs. Participants will undergo regular visits to collect clinical, serological, radiological, and genetic data at defined intervals up to 60 months after symptom onset. The study tracks disease persistence, severity using radiographic scores, and treatment use including advanced therapies. Psychosocial factors are also evaluated annually. This approach helps understand prognosis and guides future clinical care for early inflammatory arthritis patients.
CONDITIONS
Brief Title
Prognostic Evaluation of Inflammatory Polyarthritis of Recent Onset
Who Can Participate
Age: 18Years - 90Years
All Genders
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 90 years
- Diagnosis of early rheumatoid arthritis or early inflammatory arthritis
- Synovitis affecting at least 3 joints
- Symptoms lasting more than 4 weeks and less than 52 weeks
You will not qualify if you...
- Refusal or inability to provide consent
- Infectious arthritis
- Microcrystalline arthritis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Monitoring
Duration - Up to 5 years
Participants with early inflammatory polyarthritis are observed over time with regular assessments of clinical, serological, radiological, and genetic data to evaluate disease progression and outcomes without interference with their treatment.
Annual visits for up to 5 years
Trial Site Locations
Total: 1 location
1
Centre hospitalier universitaire de Sherbrooke
Sherbrooke, Quebec, Canada, J1H 4N4
Actively Recruiting
Loading map...
Research Team
G
Gilles Boire, MD, MSc
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Depressive symptoms predict future simple disease activity index scores and simple disease activity index remission in a prospective cohort of patients with early inflammatory polyarthritis.
Charlotte Leblanc-Trudeau, Patricia L Dobkin, Nathalie Carrier...
https://pubmed.ncbi.nlm.nih.gov/26209789Anti-carbamylated Protein Antibody Levels Correlate with Anti-Sa (Citrullinated Vimentin) Antibody Levels in Rheumatoid Arthritis.
Gregory J Challener, Jonathan D Jones, Adam J Pelzek...
https://pubmed.ncbi.nlm.nih.gov/26669911Serum levels of 14-3-3η protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis.
Nathalie Carrier, Anthony Marotta, Artur J de Brum-Fernandes...
https://pubmed.ncbi.nlm.nih.gov/26832367Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis.
Gilles Boire, Pierre Cossette, Artur J de Brum-Fernandes...
https://pubmed.ncbi.nlm.nih.gov/15899046Outcomes in recent-onset inflammatory polyarthritis differ according to initial titers, persistence over time, and specificity of the autoantibodies.
Marie-Caroline Guzian, Nathalie Carrier, Pierre Cossette...
https://pubmed.ncbi.nlm.nih.gov/20617532The DERAA HLA-DR alleles in patients with early polyarthritis: protection against severe disease and lack of association with rheumatoid arthritis autoantibodies.
Nathalie Carrier, Pierre Cossette, Claude Daniel...
https://pubmed.ncbi.nlm.nih.gov/19248090Predictors of pain for patients with early inflammatory polyarthritis.
Patricia L Dobkin, Aihua Liu, Michal Abrahamowicz...
https://pubmed.ncbi.nlm.nih.gov/2328124314-3-3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage.
Walter P Maksymowych, Désirée van der Heijde, Cornelia F Allaart...
https://pubmed.ncbi.nlm.nih.gov/24751211Serum C-X-C motif chemokine 13 is elevated in early and established rheumatoid arthritis and correlates with rheumatoid factor levels.
Jonathan D Jones, B JoNell Hamilton, Gregory J Challener...
https://pubmed.ncbi.nlm.nih.gov/24766912